IBA continues to reach major milestones on compact proton therapy technologies

First high energy beam extracted in IBA’s superconducting synchrocyclotron

Louvain-la-Neuve, Belgium, September 4th, 2013 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has accelerated and extracted a proton beam to its full nominal energy in its new compact synchrocyclotron.

The compact superconducting synchrocyclotron accelerates protons to an energy of 230 MeV meaning that it has now reached levels suitable for use in Pencil Beam Scanning (“PBS”) technologies. In the next few months, the machine will undergo the tests necessary for application to the competent authorities including CE Marking and the FDA. PBS technology enables millimeter precision allowing for the proton dose to be sculpted with very high levels of conformity and dose uniformity, even in complex-shaped tumors.

This accelerator will be shipped later this year to the Centre Antoine Lacassagne (CAL) in Nice, France as part of the Proteus®ONE solution. The first patients to benefit from this compact accelerator technology are expected to be treated in 2015.

The Proteus®ONE solution has been developed by IBA to allow more patients to access proton therapy. Proteus®ONE is a smaller, more affordable and faster to install proton therapy solution, encompassing the latest technologies, including IBA Pencil Beam Scanning (PBS).

Olivier Legrain, Chief Executive Officer of IBA commented: “We are delighted to have reached this key milestone in the development of this revolutionary compact proton therapy solution. Making proton therapy centers smaller and more affordable is a key in IBA’s strategy as we endeavor to make the Proteus®ONE system accessible to more patients.”

Yves Jongen, Chief Research Officer of IBA, added: “IBA’s expertise has historically been to develop cyclotrons that are better and easier to use for clinical applications. This accelerator will provide a stable and reliable proton source for proton therapy, while reducing cost of operations and maintenance. It is a key element in making proton therapy available to more oncologists and patients around the world.”
To date, three Proteus®ONE systems have been ordered.

Notes to Editors

About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide utilize IBA systems. This includes 15 proton therapy centers in operation and 11 centers under development. Over 25,000 patients have been treated on IBA equipment – more than all competitor installations combined.

About Proteus®ONE*
IBA Proteus®ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus®PLUS, developed with top clinical institutions worldwide. Proteus®ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy modality. Proteus®ONE is smaller, more affordable, easier to install, easier to operate and ultimately to finance. With Proteus®ONE, protons are possible for more patients worldwide.

*Proteus®ONE is the brand name of a new configuration of the Proteus® 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.

About IBA
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company’s primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and
equipment. IBA’s proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
Investorrelations@iba-group.com